The CheckMate 649 trial, recently published in Nature, established chemotherapy plus nivolumab as a standard in advanced, treatment-naive gastroesophageal adenocarcinoma, with best results seen in patients with high PD-L1 expression and microsatellite unstable tumors. In contrast, nivolumab plus ipilimumab, compared with chemotherapy, showed early progression and no overall survival benefit.

中文翻译：

---

联合免疫检查点阻断治疗晚期未经治疗的胃食管腺癌：寻求生物标志物以获得持久益处

最近发表在Nature 杂志上的 CheckMate 649 试验确立了化疗加 nivolumab 作为晚期、初治胃食管腺癌的标准，在高 PD-L1 表达和微卫星不稳定肿瘤的患者中观察到最佳结果。相比之下，与化疗相比，纳武利尤单抗加易普利姆玛显示出早期进展且没有总体生存获益。